janssen_latest_logo_on_sign

Janssen’s Tremfya shows long-term efficacy in moderate to severe plaque psoriasis

pharmafile | February 19, 2018 | News story | Research and Development, Sales and Marketing Janssen, Tremfyam guselkumab, pharma, plaque psoriasis, psoriasis 

Janssen has unveiled new Phase 3 trial data for its IL-23 inhibitor Tremfya (guselkumab), demonstrating that the drug was able to generate high skin clearance rates in patients with moderate to severe plaque psoriasis when administered as a long-term treatment.

The data from the 992-strong trial showed that, of the participants who achieved a 90% improvement in skin clearance according to the Psoriasis Area and Severity Index (PASI 90) at week 28, 86% went on to maintain the same level of response with continuous treatment through to week 72. This is compared to just 11.5% of the 173 patients who maintained the same level of response after being withdrawn from continued treatment with the drug. Of the total number of patients withdrawn, 87.6% achieved a PASI 90 response within six months of starting treatment.

Tremfya was most recently approved in Europe as a treatment for moderate to severe plaque psoriasis in adult patients who may benefit from systemic therapy.

“The longer-term data from VOYAGE 2 shows promising results for guselkumab as both a continuous, long-term treatment for moderate to severe plaque psoriasis, and as an option for patients who have been withdrawn from therapy and retreated,” commented study investigator Professor Kristian Reich of Dermatologikum Berlin and SCIderm Research Institute. “These data provide important information to dermatologists should they need to interrupt treatment with guselkumab for a period of time, as the findings demonstrate guselkumab quickly and robustly re-established a PASI 90 response within six months.”

Matt Fellows

Related Content

Boehringer Ingelheim’s Spevigo gains additional approvals in US and China

Boehringer Ingelheim has announced that Spevigo (spesolimab-sbzo) has been approved by the US Food and …

GSK enters agreement for license for JNJ-3089 for development of bepirovirsen

GSK and Arrowhead Pharmaceuticals have announced that they have come to an agreement with Janssen …

Janssen and Sanofi enter agreement for potential vaccine programme

Janssen Pharmaceuticals, a Johnson & Johnson company, has announced a development and commercialisation agreement with …

Latest content